MNMaissa Noaman

Maissa Noaman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maissa Noaman has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of Statistical Methodologies and Pitfalls of Dissertations Carried Out at National Cancer Institute, Cairo University

    by Rasha M Allam, Maissa K Noaman, Manar M Moneer, Inas A Elattar

    Purpose: To identify statistical errors and pitfalls in dissertations performed as part of the requirements for the Medical Doctorate (MD) degree at the National Cancer Institute (NCI), Cairo University (CU) to improve the quality of medical research. Methods: A critical assessment of 62 MD dissertations conducted in 3 departments at NCI, CU, between 2009 and 2013 was carried out regarding statistical methodology and presentation of the results. To detect differences in study characteristics over time, grouping was into two periods; 2009-2010 and 2011-2013. Results: Statistical methods were appropriate in only 13 studies (24.5%). The most common statistical tests applied were chi-square, log-rank, and Mann-Whitney tests. Four studies estimated sample size and/or power. Only 37.1% and 38.7% of dissertation results supported aims and answered the research questions, respectively. Most of results were misinterpreted (82.3%) with misuse of statistical terminology (77.4%). Tabular and graphical data display was independently informative in only 36 dissertations (58.1%) with accurate titles and labels in only 17 (27.4%). Statistical tests fulfilled the assumptions only in 29 studies; with evident misuse in 33. Ten dissertations reported non-significance regarding their primary outcome measure; the median power of the test was 35.5% (range: 6-60%). There was no significant change in the characteristics between the time periods. Conclusion: MD dissertations at NCI have many epidemiological and statistical defects that may compromise the external validity of the results. It is recommended to involve a biostatistician from the very start to improve study design, sample size calculation, end points estimation and measures.


  • Open Access

    Circulating fibrocytes are an indicator of severity and exacerbation in chronic obstructive pulmonary disease

    by Safy Kaddah, Samah Selim, Laila Rashed, Maissa Noaman

    RationaleChronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation that is associated with an enhanced inflammatory response in the airways and the lung. The remodeling process in COPD is greatly under the influence of growth factors. Lung fibroblasts in COPD demonstrated alterations in its functional capacity that is mediated by TGF-β1, therefore, could play a role in the pathogenesis of COPD. Fibrocytes are bone marrow derived cells that migrate to the injured sites and differentiate into fibroblast-like cells.ObjectivesTo test the hypothesis that assay of circulating fibrocytes may provide a biomarker for exacerbation and severity of COPD.MethodsFibrocytes were defined by flow cytometry and quantified in fifty male patients with stable COPD and during exacerbation. We investigated the clinical and prognostic value of fibrocytes by comparison with standard clinical parameters. Thirteen healthy subjects were selected as control.ResultsFibrocytes were significantly elevated in stable COPD patients (n=25), with a further increase during exacerbation (n=25; P<0.001 vs. control subjects n=13). Correlation analysis between fibrocyte counts and mMRC score, 6-MWT, BODE index, arterial oxygen saturation, pre- and post-bronchodilator FEV1/FVC, FEV1, FVC and FEF25–75 showed a direct relationship in COPD patients. There was a direct correlation between fibrocytes with the mMRC score and the serum levels of TGF-β1 only in COPD patients in exacerbations (n=25).ConclusionsFibrocytes are an indicator of COPD exacerbation and might be useful as a clinical (bio) marker for disease progression